Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 24;13:829228. doi: 10.3389/fimmu.2022.829228

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Vietzen, Döhler, Tran, Süsal, Halloran, Eskandary, Herz, Mayer, Kozakowski, Wahrmann, Ely, Haindl, Puchhammer-Stöckl and Böhmig

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Study flow chart. Systematic cross-sectional antibody-mediated rejection (ABMR) screening of a cohort of 741 kidney transplant recipients (BORTEJECT trial) led to the identification of 111 donor-specific antibody (DSA)-positive recipients. Eighty-six DSA+ patients underwent protocol biopsies. For all 86 subjects (primary study cohort) adequate material for KLRC2 genotyping was available. A control group of 106 recipients was defined by propensity score matching as described in the methods section. A large prospective multicenter cohort (Collaborative Transplant Study, CTS; 1,860 recipient/donor pairs) was included to assess associations of genotyping results in relation to long-term allograft outcomes. eGFR, estimated glomerular filtration rate.